Beam Therapeutics Inc. (BEAM) Stock Price & Analysis
Beam Therapeutics Inc. (BEAM) closed at USD 28.78 on Wednesday, October 28, 2026, up 15.58% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 24.9; the Oct 28, 2026 session ranged USD 24.5–28.86 on volume of 4,999,014 shares. Market capitalization is $2.97B, with a 52-week range of USD 20.23–38.26 (NMS). Source: Nexqual, retrieved October 28, 2026 at 22:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BEAM.md
Key facts (BEAM)
- Last four reported quarters (through Jun 30, 2026): revenue $156M, net income -$85.4M (-54.7% margin), free cash flow -$373M (SEC filings).
- Insider open-market sales, last ~7 months: 6 Form 4 filings, $13.4M; 1 not under a Rule 10b5-1 plan ($10.0M); 0 by opportunistic insiders, 4 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.07 on a 1–5 scale) (15 analysts), mean target USD 49.31 (range 26–80).
- Total return with dividends: 1Y +16.2% vs S&P 500 +13.6%; 5Y -67.6% vs S&P 500 +79.8%.
- Next earnings: 2026-11-03, EPS estimate USD -1.17, revenue estimate $10.0M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BEAM)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $51.8M | $60.9M | $378M | $63.5M | $140M | $156M |
| Operating income | -$392M | -$338M | -$176M | -$416M | -$384M | -$378M |
| Net income | -$371M | -$289M | -$133M | -$377M | -$80.0M | -$85.4M |
| EPS (diluted) | -$5.77 | -$4.13 | -$1.72 | -$4.58 | -$0.81 | — |
| Free cash flow | -$113M | -$26.4M | -$183M | -$356M | -$360M | -$373M |
| Operating margin | -757.0% | -555.6% | -46.7% | -654.3% | -274.6% | -242.3% |
| Net margin | -714.9% | -474.5% | -35.1% | -593.1% | -57.2% | -54.7% |
| Revenue growth | +215916.7% | +17.5% | +520.0% | -83.2% | +120.0% | — |
| Cash + short-term investments | $966M | $1.10B | $1.20B | $851M | $1.20B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BEAM)
P/S 19.1x · EV/Sales 12.0x · P/B 2.8x · FCF yield -12.54% · Earnings yield -2.87% · Net cash $1.10B · EV $1.87B
Insider sales (SEC Form 4, open-market, last ~7 months) (BEAM)
5 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-10-15…2026-10-16 | Evans John M. | CEO | 50,000 | $1.2M | 4.2% | Yes (adopted June 16, 2026) | Routine (sold in Apr each year 2023–2025; this trade is outside those months) |
| 2026-10-01 | Cavanagh Bethany J | SVP, Finance and Treasurer | 187 | $5K | 0.4% | Yes (adopted August 9, 2024) | Too little history (no open-market trades in 2023) |
| 2026-07-27 | Simon Amy | Chief Medical Officer | 16,667 | $429K | 16.3% | Yes (adopted March 27, 2026) | Routine (sold in Apr & Jul each year 2023–2025) |
| 2026-06-30 | Simon Amy | Chief Medical Officer | 373 | $13K | 0.4% | Yes (adopted May 19, 2023) | Routine (sold in Apr & Jul each year 2023–2025; this trade is outside those months) |
| 2026-06-29…2026-06-30 | Evans John M. | CEO | 50,000 | $1.7M | 4.2% | Yes (adopted May 16, 2025) | Routine (sold in Apr each year 2023–2025; this trade is outside those months) |
| 2026-06-25…2026-06-26 | Fmr Llc | 284,860 | $10.0M | 14.4% | No | Too little history (no open-market trades in 2023) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (BEAM)
Consensus Buy (mean 2.07 on a 1–5 scale), 15 analysts; mean target USD 49.31 (low 26, high 80).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-28 | Wedbush | Target lowered | Outperform | $65 → $28 |
| 2026-10-15 | HC Wainwright & Co. | Reiterated | Buy | $80 |
| 2026-10-14 | Wedbush | Reiterated | Outperform | $65 |
| 2026-09-09 | Wedbush | Reiterated | Outperform | $65 |
| 2026-08-25 | HC Wainwright & Co. | Reiterated | Buy | $80 |
| 2026-07-08 | B of A Securities | Reiterated | Buy | $47 |
| 2026-07-07 | HC Wainwright & Co. | Reiterated | Buy | $80 |
Total return (dividends reinvested) (BEAM)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +16.2% | -67.6% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +16.3% | -20.1% |
| Volatility (annualized) | 70.6% | 68.3% |
| Max drawdown | -39.1% (Jul 2026→Sep 2026) | -83.4% (Nov 2021→Mar 2025) |
BEAM earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 4, 2026 | Quarter ended Jun 30, 2026 | −$1.18 | −$1.13 | Miss −4.4% | +4.5% |
| May 7, 2026 | Quarter ended Mar 31, 2026 | −$0.91 | −$1.01 | Beat +9.9% | -0.1% |
| Feb 24, 2026 | Quarter ended Dec 31, 2025 | $2.33 | −$1.12 | Beat +$3.45 | +4.5% |
| Jan 12, 2026 | Quarter ended Dec 31, 2025 | $2.33 | −$1.12 | Beat +$3.45 | +25.4% |
| Nov 4, 2025 | Quarter ended Sep 30, 2025 | −$1.10 | −$1.01 | Miss −8.9% | -4.9% |
| Aug 5, 2025 | — | — | — | — | -4.3% |
| May 6, 2025 | — | — | — | — | -18.1% |
| Feb 25, 2025 | — | — | — | — | -9.4% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
BEAM recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Aug 14, 2026 | Schedule 13G/A | ARK Investment Management LLC, Catherine D. Wood: 9.9% of shares, passive 5%+ holder (amended) |
| Aug 13, 2026 | Schedule 13G/A | Farallon Capital Management, L.L.C., Farallon Capital Partners, L.P.: 10.0% of shares, passive 5%+ holder (amended) |
| Aug 4, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 4, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
BEAM suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | Editas Medicine, Inc. (EDIT) | “License agreement with Editas Medicine, Inc.” |
| Partner | Pfizer (PFE) | “In December 2021, we entered into a four-year research collaboration agreement with Pfizer Inc., or Pfizer, focused on in vivo base editing programs for three targets for rare genetic diseases.” |
| Partner | Bio Palette | “Certain of the patents, or the Kobe Patents, licensed to us under the Bio Palette License Agreement were licensed to Bio Palette from Kobe University under a license agreement we refer to as the Kobe Head License.” |
| Partner | Eli Lilly (LLY) | “Under the terms of the Lilly Agreement, we received a $200.0 million payment and are eligible to receive up to $350.0 million in potential future development-stage payments upon the completion of certain clinical, regulatory and alliance events, of which $25.0 million has been received through December 31, 2025.” |
| Partner | Broad Institute | “Certain of the patents licensed to us under the Editas License Agreement were licensed to Editas from Broad Institute and Harvard and certain of the patents for which we have an option to obtain a license were licensed to Editas from the Massachusetts General Hospital, or MGH.” |
| Partner | Apellis Pharmaceuticals | “In June 2021, we entered into a research collaboration agreement, or the Apellis Agreement, with Apellis Pharmaceuticals, Inc., or Apellis, focused on the use of our base editing technology to discover new treatments for complement system-driven diseases.” |
| Partner | Orbital Therapeutics | “We are party to a license agreement, or the Orbital Agreement, with Orbital, pursuant to which each of us have granted the other non-exclusive licenses to certain technology that is necessary or reasonably useful for the non-viral delivery or the design or manufacture of RNA for the prevention, treatment or diagnosis of human disease.” |
| Partner | Verve Therapeutics | “We are party to a license agreement, or the Verve Agreement, with Verve Therapeutics, Inc., or Verve, pursuant to which we granted Verve exclusive worldwide licenses under our base editing technologies for human therapeutic applications against a total of three liver-mediated, cardiovascular disease targets, which consist of PCSK9, ANGPTL3 and an undisclosed target.” |
| Partner | General | “Certain of the patents licensed to us under the Editas License Agreement were licensed to Editas from Broad Institute and Harvard and certain of the patents for which we have an option to obtain a license were licensed to Editas from the Massachusetts General Hospital, or MGH.” |
| Partner | ALEXANDRIA REAL ESTATE EQUITIES, INC. (ARE) | “Additionally, we entered into a lease agreement with Alexandria Real Estate Equities, Inc. pursuant to which we built” |
Quoted from the company's 10-K filed Feb 24, 2026.
Companies that name BEAM in their SEC reports
| Relationship to BEAM | Company | Filing | Sentence |
|---|---|---|---|
| partner | Editas Medicine, Inc. (EDIT) | 10-K Mar 9, 2026 | “Beam Therapeutics License Agreement” |
| partner | Prime Medicine, Inc. (PRME) | 10-K Mar 3, 2026 | “•We may enter into collaborations with collaborators and strategic partners such as Beam Therapeutics Inc., or Beam, or other third parties for the research, development, delivery, manufacturing and commercialization of Prime Editing technology and certain of the product candidates we may develop.” |
| partner | Sana Biotechnology, Inc. (SANA) | 10-K Mar 3, 2026 | “License Agreement with Beam” |
BEAM company outlook (results filed Aug 4, 2026)
- “Biologics License Application (BLA) Submission Expected as Early as Year-End 2026 Clinical Trial Start-up Activities Underway Following U.S.”
- “Cash Runway Expected to Support Operating Plans into mid-2029 Cambridge, Mass., August 4, 2026 – Beam Therapeutics Inc.”
- “Looking ahead, we believe Beam is positioned to achieve several important milestones, including updated clinical data for BEAM-302 at the ERS Congress, rapid enrollment in the BEAM-302 pivotal cohort, first-in-human data for BEAM-301 in GSDIa, and the expected BLA submission for risto-cel.”
- “BEAM-301: BEAM-301 aims to correct one of the most common disease-causing mutations, R83C, in patients with glycogen storage disease type Ia (GSDIa). • BEAM-301 is currently being evaluated in an open-label Phase 1/2 dose-exploration trial in patients with GSDIa. • Beam expects to report initial clinical data in 2026.”
Quoted word-for-word from the SEC 8-K results press release.
BEAM analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-1.17 | $-1.17 | $0.00 | $10.0M | 13 |
| Next quarter (ends Dec 2026) | $-1.19 | $-1.20 | +$0.01 | $11.6M | 13 |
| Current fiscal year (ends Dec 2026) | $-4.46 | $-4.43 | −$0.02 | $53.2M | 14 |
| Next fiscal year (ends Dec 2027) | $-4.74 | $-4.73 | −$0.01 | $61.8M | 14 |
BEAM options: expected move
Options price a move of about ±15.4% (±$4.38) by Nov 20, 2026, which includes earnings on Nov 3, 2026. Over the last 8 reports the stock moved ±8.9% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 77.2% | ±15.4% |
| Dec 18, 2026 | 51 | 66.8% | ±19.7% |
| Jan 15, 2027 | 79 | 68.3% | ±24.9% |
| Feb 19, 2027 | 114 | 60.3% | ±26.5% |
| May 21, 2027 | 205 | 78.1% | ±45.3% |
30-day implied volatility 69.8% vs 62.9% realized over the last 30 trading days. Put/call ratio (volume) 0.08. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 28, 2026 at 22:21 UTC)
| Price | USD 28.78 |
|---|---|
| Change | ▲ 15.58% (up) |
| Previous Close | USD 24.9 |
| Open | USD 24.61 |
| Day Range | USD 24.5 – 28.86 |
| 52-Week Range | USD 20.23 – 38.26 |
| Volume | 4,999,014 shares |
| Market Cap | $2.97B |
| Exchange | NMS |
Technical Analysis (BEAM)
Nexqual's technical model rates BEAM "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 28, 2026 at 22:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 68.83 (neutral) |
| vs SMA50 | Above (USD 25.96) |
| MACD | 0.04 (positive) |
Analyst Ratings (BEAM)
Wall Street analysts rate BEAM "Buy" based on 15 analysts, with a mean price target of USD 49.31 (range USD 26–80), per Nexqual as of October 28, 2026 at 22:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 49.31 |
| High Target | USD 80 |
| Low Target | USD 26 |
| Buy / Hold / Sell | 13 / 2 / 0 |
Earnings (BEAM)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -1.17 |
| Revenue Estimate | $9.96M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -1.18 vs est -1.13 ▼ miss |
| 2026-03-31 | USD -0.91 vs est -1.01 ▲ beat |
| 2025-12-31 | USD 2.33 vs est -1.12 ▲ beat |
| 2025-09-30 | USD -1.1 vs est -1.01 ▼ miss |
Source: Nexqual, October 28, 2026 at 22:21 UTC.
Financials & Fundamentals (BEAM)
| Total Revenue | $156.04M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -94.20% |
| Gross Margin | -161.91% |
| Operating Margin | -25827.14% |
| Profit Margin | -55.45% |
| ROE | -8.18% |
| Debt / Equity | 0.23 |
| Current Ratio | 14.57 |
| Total Cash | $1.15B |
| Total Debt | $247.36M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$372.77M (-238.9% of revenue) |
Source: Nexqual, October 28, 2026 at 22:21 UTC.
Financial Health Score (BEAM)
Nexqual rates Beam Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of October 28, 2026 at 22:21 UTC.
| Growth | Strong — Revenue +120% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $1.20B cash and investments vs $100M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$373M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -8%, ROA -6.2% (last 4 quarters, SEC) |
Ownership (BEAM)
| Insider Ownership | +1.20% |
|---|---|
| Institutional Ownership | +107.88% |
| Shares Outstanding | 103.29M |
| Float | 88.33M |
| Short % of Float | +39.28% |
Source: Nexqual, October 28, 2026 at 22:21 UTC.
Leadership (BEAM)
Beam Therapeutics Inc. is led by John M. Evans, CEO & Director, per Nexqual as of October 28, 2026 at 22:21 UTC.
| CEO & Director | John M. Evans |
|---|---|
| President | Giuseppe Ciaramella |
| Chief Financial Officer | Sravan Kumar Emany |
| Chief Technology Officer | Manmohan Singh |
Major Backers & Investors (BEAM)
Notable institutional backers of Beam Therapeutics Inc. include FMR, LLC, Farallon Capital Management LLC, ARK Invest, according to Nexqual as of October 28, 2026 at 22:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 12.21% |
| Farallon Capital Management LLC | 9.91% |
| ARK Invest | 9.91% |
| Fidelity | 4.4% |
| Arch Venture Management, Llc | 4.4% |
| Amova Asset Management Americas Inc | 3.35% |
| Sumitomo Mitsui Trust Group, Inc. | 3.35% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 9.21% |
| BlackRock | 8.71% |
| State Street | 5.64% |
Source: Nexqual, October 28, 2026 at 22:21 UTC.
From Beam Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)
Key Strengths & Strategy (as disclosed to the SEC)
- Overall, we are seeking to build the leading integrated platform for precision genetic medicine, which may have broad therapeutic applicability and the potential to transform the field of precision genetic medicines.
- In the future, if our products receive regulatory approval, we may be eligible to apply for PTEs on patents covering such products, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such PTE should be granted, and if granted, the length of such PTE.
- We seek to protect our proprietary technology and processes, in part, by confidentiality agreements with our employees, consultants, scientific advisors, and contractors.
- We are a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines.
Partnerships
- We may elect to enter into a 50-50 U.S. co-development and co-commercialization agreement with Apellis with respect to one program licensed under the collaboration.
- We are permitted to further sublicense our rights under the Harvard License Agreement to third parties, provided that any such sublicense agreement with a third party must remain in compliance with and be consistent with the terms of the Harvard License Agreement, and certain rights granted to us under the Harvard License Agreement can only be sublicensed to bona fide collaboration partners who are working with us to develop one or more licensed products.
Legal & Regulatory Risks (Item 1A, quoted)
- Regulatory requirements governing genetic medicines, and in particular any novel genetic medicines we may develop, have changed frequently and may continue to change in the future.
- Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.
- Any product for which we obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with any such product following approval.
- We may seek PRIME Designation in the EU for our product candidates, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ORKA | Oruka Therapeutics, Inc. | USD 95.97 | ▲ 0.17% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 91.97 | ▼ 0.23% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.81 | ▲ 1.58% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.9 | ▲ 2.14% |
| AXSM | Axsome Therapeutics, Inc. | USD 143.51 | ▲ 0.92% |
| PRAX | Praxis Precision Medicines, Inc | USD 285.48 | ▲ 6.69% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 28, 2026 at 22:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt